These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 23201857)

  • 1. Treatment 2.0: catalyzing the next phase of treatment, care and support.
    Duncombe C; Ball A; Passarelli C; Hirnschall G
    Curr Opin HIV AIDS; 2013 Jan; 8(1):4-11. PubMed ID: 23201857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance.
    Bennett DE; Bertagnolio S; Sutherland D; Gilks CF
    Antivir Ther; 2008; 13 Suppl 2():1-13. PubMed ID: 18578063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges.
    Vitoria M; Vella S; Ford N
    Curr Opin HIV AIDS; 2013 Jan; 8(1):12-8. PubMed ID: 23188179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of HIV in resource limited settings.
    McCutchan JA
    Curr Opin Infect Dis; 2009 Oct; 22(5):464-70. PubMed ID: 19730283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.
    Bishai D; Colchero A; Durack DT
    AIDS; 2007 Jun; 21(10):1333-40. PubMed ID: 17545710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seizing the opportunity to capitalise on the growing access to HIV treatment to expand HIV prevention.
    Gayle H; Lange JM
    Lancet; 2004 Jul 3-9; 364(9428):6-8. PubMed ID: 15234835
    [No Abstract]   [Full Text] [Related]  

  • 7. Achieving the WHO/UNAIDS antiretroviral treatment 3 by 5 goal: what will it cost?
    Gutierrez JP; Johns B; Adam T; Bertozzi SM; Edejer TT; Greener R; Hankins C; Evans DB
    Lancet; 2004 Jul 3-9; 364(9428):63-4. PubMed ID: 15234857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and behavioral characteristics of adults receiving medical care for HIV infection --- Medical Monitoring Project, United States, 2007.
    Blair JM; McNaghten AD; Frazier EL; Skarbinski J; Huang P; Heffelfinger JD
    MMWR Surveill Summ; 2011 Sep; 60(11):1-20. PubMed ID: 21881551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Brazilian experiment: HIV drugs for all.
    Flaer PJ; Younis MZ
    J Health Care Finance; 2009; 36(2):90-6. PubMed ID: 20499725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. World Health Organization/HIVResNet Drug Resistance Laboratory Strategy.
    Bertagnolio S; Derdelinckx I; Parker M; Fitzgibbon J; Fleury H; Peeters M; Schuurman R; Pillay D; Morris L; Tanuri A; Gershy-Damet GM; Nkengasong J; Gilks CF; Sutherland D; Sandstrom P
    Antivir Ther; 2008; 13 Suppl 2():49-57. PubMed ID: 18575191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Setting targets for universal access to HIV prevention, treatment and care for injecting drug users (IDUs): towards consensus and improved guidance.
    Donoghoe MC; Verster A; Pervilhac C; Williams P
    Int J Drug Policy; 2008 Apr; 19 Suppl 1():S5-14. PubMed ID: 18243681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. User fees and access to ARV treatment for persons living with HIV/AIDS: implementation and challenges in Burkina Faso, a limited-resource country.
    Kouanda S; Bocoum FY; Doulougou B; Bila B; Yameogo M; Sanou MJ; Sawadogo M; Sondo B; Msellati P; Desclaux A
    AIDS Care; 2010 Sep; 22(9):1146-52. PubMed ID: 20824567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [1986-2006: 20 years of failed international policy to control AIDS in Africa].
    Kerouedan D
    Med Trop (Mars); 2007 Oct; 67(5):515-28. PubMed ID: 18225738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing perinatal HIV transmission in developing countries through antenatal and delivery care, and breastfeeding: supporting infant survival by supporting women's survival.
    Berer M
    Bull World Health Organ; 1999; 77(11):871-7. PubMed ID: 10612882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Access to antiretroviral treatment in developing countries: Which financing strategies are possible?
    Beaulière A; Le Maux A; Trehin C; Perez F
    Rev Epidemiol Sante Publique; 2010 Jun; 58(3):171-9. PubMed ID: 20430553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are countries using global fund support to implement HIV drug resistance surveillance? A review of funded HIV grants.
    Kelley KF; Caudwell E; Xueref S; Ha TH; Bertagnolio S
    Clin Infect Dis; 2012 May; 54 Suppl 4():S250-3. PubMed ID: 22544183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free care at the point of service delivery: a key component for reaching universal access to HIV/AIDS treatment in developing countries.
    Souteyrand YP; Collard V; Moatti JP; Grubb I; Guerma T
    AIDS; 2008 Jul; 22 Suppl 1():S161-8. PubMed ID: 18664948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults.
    Bachmann MO
    AIDS Care; 2006 Feb; 18(2):109-20. PubMed ID: 16338768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethical and programmatic challenges in antiretroviral scaling-up in Malawi: challenges in meeting the World Health Organization's "Treating 3 million by 2005" initiative goals.
    Muula AS
    Croat Med J; 2004 Aug; 45(4):415-21. PubMed ID: 15311413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.